ESSA Pharma Inc. (EPIX)
NASDAQ: EPIX · IEX Real-Time Price · USD
6.90
+0.18 (2.68%)
Apr 19, 2024, 10:44 AM EDT - Market open
Company Description
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer.
The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
ESSA Pharma Inc.
| Country | Canada |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 50 |
| CEO | Dr. David Ross Parkinson M.D. |
Contact Details
Address: Suite 720, 999 West Broadway Vancouver, A1 V5Z 1K5 British Columbia, Canada | |
| Phone | (778) 331-0962 |
| Website | essapharma.com |
Stock Details
| Ticker Symbol | EPIX |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001633932 |
| CUSIP Number | 29668H708 |
| ISIN Number | CA29668H7085 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Ross Parkinson M.D. | President, Chief Executive Officer and Director |
| David S. Wood C.M.A., CPA, CMA, CPA, M.B.A., MBA | Chief Financial Officer |
| Peter A. Virsik M.B.A., M.S. | Executive Vice President and Chief Operating Officer |
| Dr. Alessandra Cesano M.D., Ph.D. | Chief Medical Officer and Executive Vice President |
| Chandtip Chandhasin | Executive |
| Erica Osbourne | Executive |
| Erin Rudsinski | Executive |
| Loleta Harris | Executive |
| Neil Thapar | Executive |
| Nkengyal Barber | Executive |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 5, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 5, 2024 | 144 | Filing |
| Mar 7, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | 10-Q | Quarterly Report |
| Feb 13, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 29, 2024 | 8-K | Current Report |